Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary
embolism, is a common condition associated with a significant clinical and economic …

The first-line treatment of venous thromboembolisms (VTE) is anticoagulant therapy, and
unfractionated heparin and warfarin are used in Japan. However, as both drugs require …

The current treatment of venous thromboembolism (VTE, ie deep-vein thrombosis [DVT] and
pulmonary embolism [PE]), is challenging because of the need for a two drug regimen …

Several oral direct anti-Xa agents and one antithrombin agent are currently under clinical
development for the prevention and treatment of venous thromboembolism (VTE). The anti …

Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism,
both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban …

Opinion statement Anticoagulation therapy remains the cornerstone for prevention and
treatment of venous thromboembolism. Currently available parenteral anticoagulants, such …

Following the landmark study by Barritt and Jordan in 1960, in which patients with venous
thromboembolism (VTE) were randomized to no treatment or a combination of heparin and …

Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism,
is the third most common cause of vascular death after myocardial infarction and stroke …

Within the past decade nonvitamin K oral anticoagulants have emerged as the standard of
care for the prevention and treatment of thromboembolic disorders, however safety of …